Observational study for treatment outcome in patients with HER2-positive metastatic breast cancer who received pertuzumab combination chemotherapy.
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000012210
- Lead Sponsor
- Kurume University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) Physician judged improper to entry this trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Response rate Progression-free survival Overall survival Time to treatment failure The incidence of the adverse event (such as infusion reaction and decreasing of LVEF) Treatment line Treatment regimen